Pelvis Organ Prolapse: What can be done to prevent it?
The word “prolapse” comes from a Latin word meaning “to fall out of place,” which is an apt description of what happens with pelvic organ prolapse, or POP. POP occurs when an organ in the pelvic region (typically the bladder, uterus, or part of the vagina) “falls” and shifts position, sometimes protruding outside of the vagina. Urinary incontinence is the most common symptom of POP.
As of 2009, approximately 3.3 million women in the US alone were estimated to be affected by POP. Based on census data and an aging population, the incidence of women with POP is expected to increase dramatically. By the year 2050, the number of women undergoing surgery for POP is projected to increase by nearly 50%. This data forewarns us that approximately 1 out of every 5 women in the US will undergo some sort of surgery for pelvic organ prolapse in her lifetime. That’s a lot of POP—and a lot of surgery!
So why have so few women heard of pelvic organ prolapse?
Your Access To Compounded Medication Is At Risk!
If you already sent a message to Congress, thank you! If you have not, this threat is still very real and you can make a big difference by sending a message to Congress now!
Last month we told you how S959 can affect you and the BHRT you take:
- FDA would be given the authority to declare BHRT to be "copies" of drug-company products that cannot be compounded, even though the products you use are not commercially available.
- A doctor could use an "exception" in the bill to continue a woman's prescription, but he or she could be required to document a clinical difference in using compounded BHRT as opposed to drug-company products. Many women and men have trouble finding the personalized, natural treatment they need to control their symptoms. This could make it even harder.
- FDA has been openly hostile to BHRT. According to its literature, "'BHRT is a marketing term not recognized by the FDA." With a hostile attitude that refuses to even recognize the important medication that countless women and men take as legitimate, what do you think FDA will do when they get full authority to determine whether women or men can have access to BHRT? And the drug companies would love to eliminate the competition for their synthetic hormones.
A revised draft of Senate Bill S. 959 is likely to go to the floor for a vote well before the end of July.
In addition, The House of Representatives has drafted its own human health compounding legislation, led by Representative Morgan Griffith (R-VA). It is now in draft form only and takes an entirely different approach than the Senate to solving the problem caused by one rogue pharmacy in Massachusetts that set-off this legislative furor.
We will keep you updated as the legislation continues. In the meantime, if you have not expressed your concerns to your representatives in Congress, please take time to visit MyMedsMatter.com and submit your message. It takes a minute or two.
Thank you for your advocacy,
Women’s Health Pharmacy Staff
Treating Multiple Sclerosis with Sex Hormones
Written by Kathy Lynch, PharmD - Women's International Pharmacy
Multiple Sclerosis (MS) is an autoimmune disorder characterized by inflammation and nervous system degeneration. Both estrogen and testosterone exhibit anti-inflammatory and neuro-protective effects when administered to MS patients in studies.
Male MS patients were treated with 100 mg of transdermal testosterone daily. At the end of the 12-month treatment period, cognitive performance improved while brain atrophy diminished. When female MS patients were treated with 8 mg of oral estriol daily for 6 months, evidence of lesions on MRIs decreased while brain function increased.
In addition, female MS patients are often plagued with chronic urinary tract infections (UTIs). Intravaginal estriol significantly decreases UTIs in postmenopausal women.
Further studies regarding hormones in the treatment of MS are ongoing.
“Estrogen and Testosterone Therapies in Multiple Sclerosis” by S.M. Gold and R.R. Voskuhl; Prog Brain Res; 2009; 175:239-251.
“A Controlled Trial of Intravaginal Estriol in Postmenopausal Women with Recurrent Urinary Tract Infections” by R. Raz and W.E. Stamm; N Engl J Med; 329(11):753-756.